Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

ERF deletion rescues RAS deficiency in mouse embryonic stem cells.

Mayor-Ruiz C, Olbrich T, Drosten M, Lecona E, Vega-Sendino M, Ortega S, Dominguez O, Barbacid M, Ruiz S, Fernandez-Capetillo O.

Genes Dev. 2018 Apr 12. doi: 10.1101/gad.310086.117. [Epub ahead of print]

PMID:
29650524
2.

The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.

Simón-Carrasco L, Jiménez G, Barbacid M, Drosten M.

Cell Cycle. 2018 Mar 26:1-33. doi: 10.1080/15384101.2018.1450029. [Epub ahead of print]

PMID:
29578365
3.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N.

Cancer Discov. 2018 Feb 26. doi: 10.1158/2159-8290.CD-17-1452. [Epub ahead of print]

PMID:
29483135
4.

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M.

Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.

PMID:
29395869
5.

Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma.

Simón-Carrasco L, Graña O, Salmón M, Jacob HKC, Gutierrez A, Jiménez G, Drosten M, Barbacid M.

Genes Dev. 2017 Jul 15;31(14):1456-1468. doi: 10.1101/gad.300244.117. Epub 2017 Aug 21.

6.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N.

Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.

7.

Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Drosten M, Guerra C, Barbacid M.

Cold Spring Harb Perspect Med. 2017 Aug 4. pii: a031542. doi: 10.1101/cshperspect.a031542. [Epub ahead of print]

PMID:
28778964
8.

A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer.

Forés M, Simón-Carrasco L, Ajuria L, Samper N, González-Crespo S, Drosten M, Barbacid M, Jiménez G.

PLoS Genet. 2017 Mar 9;13(3):e1006622. doi: 10.1371/journal.pgen.1006622. eCollection 2017 Mar.

9.

Clasp2 ensures mitotic fidelity and prevents differentiation of epidermal keratinocytes.

Shahbazi MN, Peña-Jimenez D, Antonucci F, Drosten M, Perez-Moreno M.

J Cell Sci. 2017 Feb 15;130(4):683-688. doi: 10.1242/jcs.194787. Epub 2017 Jan 9.

10.

Genetic Validation of Cell Proliferation via Ras-Independent Activation of the Raf/Mek/Erk Pathway.

Lechuga CG, Simón-Carrasco L, Jacob HK, Drosten M.

Methods Mol Biol. 2017;1487:269-276.

PMID:
27924574
11.

H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.

Drosten M, Simón-Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HK, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M.

Cancer Res. 2017 Feb 1;77(3):707-718. doi: 10.1158/0008-5472.CAN-16-2925. Epub 2016 Nov 21.

12.

Ras and p53: An unsuspected liaison.

Drosten M, Barbacid M.

Mol Cell Oncol. 2015 Jan 23;3(2):e996001. doi: 10.1080/23723556.2014.996001. eCollection 2016 Mar.

13.

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.

Drosten M, Barbacid M.

J Mol Med (Berl). 2016 Feb;94(2):121-35. doi: 10.1007/s00109-015-1360-5. Epub 2015 Nov 3. Review.

PMID:
26526121
14.

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

Drosten M, Sum EY, Lechuga CG, Simón-Carrasco L, Jacob HK, García-Medina R, Huang S, Beijersbergen RL, Bernards R, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15155-60. doi: 10.1073/pnas.1417549111. Epub 2014 Oct 6.

15.

Ras in epidermal proliferation.

Drosten M, Lechuga CG, Barbacid M.

Oncotarget. 2014 Jul 30;5(14):5194-5. No abstract available.

16.

Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications.

Azrak SS, Ginel-Picardo A, Drosten M, Barbacid M, Santos E.

BMC Genomics. 2013 Oct 25;14:731. doi: 10.1186/1471-2164-14-731.

17.

Genetic analysis of Ras genes in epidermal development and tumorigenesis.

Drosten M, Lechuga CG, Barbacid M.

Small GTPases. 2013 Oct-Dec;4(4):236-41. doi: 10.4161/sgtp.26905. Epub 2013 Oct 22. Review.

18.

Ras signaling is essential for skin development.

Drosten M, Lechuga CG, Barbacid M.

Oncogene. 2014 May 29;33(22):2857-65. doi: 10.1038/onc.2013.254. Epub 2013 Jul 8.

PMID:
23831572
19.

Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M, Barbacid M, Kolch W.

Mol Cell. 2011 Dec 23;44(6):893-906. doi: 10.1016/j.molcel.2011.10.016.

20.

K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.

Alvarez-Moya B, López-Alcalá C, Drosten M, Bachs O, Agell N.

Oncogene. 2010 Nov 4;29(44):5911-22. doi: 10.1038/onc.2010.298. Epub 2010 Aug 30.

PMID:
20802526
21.

Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival.

Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, Castellano E, Guerra C, Santos E, Barbacid M.

EMBO J. 2010 Mar 17;29(6):1091-104. doi: 10.1038/emboj.2010.7. Epub 2010 Feb 11.

22.

Using cells devoid of RAS proteins as tools for drug discovery.

Urosevic J, Sum EY, Moneo V, Drosten M, Dhawahir A, Becerra M, Carnero A, Barbacid M.

Mol Carcinog. 2009 Nov;48(11):1038-47. doi: 10.1002/mc.20555.

PMID:
19526460
23.

Mechanisms of Disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy.

Drosten M, Pützer BM.

Nat Clin Pract Oncol. 2006 Oct;3(10):564-74. Review.

PMID:
17019434
24.

Evaluation of potential mechanisms underlying genotype-phenotype correlations in multiple endocrine neoplasia type 2.

Mise N, Drosten M, Racek T, Tannapfel A, Pützer BM.

Oncogene. 2006 Oct 26;25(50):6637-47. Epub 2006 May 22.

PMID:
16715139
25.

Novel SRESPHP peptide mediates specific binding to primary medullary thyroid carcinoma after systemic injection.

Böckmann M, Hilken G, Schmidt A, Cranston AN, Tannapfel A, Drosten M, Frilling A, Ponder BA, Pützer BM.

Hum Gene Ther. 2005 Nov;16(11):1267-75.

PMID:
16259560
26.

Discovery of targeting peptides for selective therapy of medullary thyroid carcinoma.

Böckmann M, Drosten M, Pützer BM.

J Gene Med. 2005 Feb;7(2):179-88.

PMID:
15508130
27.

Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma.

Drosten M, Hilken G, Böckmann M, Rödicker F, Mise N, Cranston AN, Dahmen U, Ponder BA, Pützer BM.

J Natl Cancer Inst. 2004 Aug 18;96(16):1231-9.

PMID:
15316058
28.

The RET proto-oncogene: a potential target for molecular cancer therapy.

Pützer BM, Drosten M.

Trends Mol Med. 2004 Jul;10(7):351-7. Review.

PMID:
15242684
29.

Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model.

Drosten M, Stiewe T, Pützer BM.

Hum Gene Ther. 2003 Jul 1;14(10):971-82.

PMID:
12869215
30.

Gene therapeutic approaches for medullary thyroid carcinoma treatment.

Drosten M, Pützer BM.

J Mol Med (Berl). 2003 Jul;81(7):411-9. Epub 2003 Jun 14. Review.

PMID:
12811413
31.

Supplemental Content

Loading ...
Support Center